Ignite Creation Date:
2024-05-06 @ 2:26 PM
Last Modification Date:
2024-10-26 @ 1:30 PM
Study NCT ID:
NCT04310592
Status:
RECRUITING
Last Update Posted:
2023-02-16
First Post:
2020-03-12
Brief Title:
Natural Killer Cell CYNK-001 Infusions in Adults With AML
Sponsor:
Celularity Incorporated
Organization:
Celularity Incorporated
Study Overview
Official Title:
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells CYNK-001 With or Without Recombinant Human Interleukin-2 rhIL-2 in Adults With Primary or Secondary Acute Myeloid Leukemia AML in Morphologic Complete Remission With Minimal Residual Disease MRD or RelapsedRefractory RR AML
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CYNK001AML01
Brief Summary:
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer NK cells derived from human placental CD34 cells and culture-expanded CYNK-001 cells will be given after lymphodepleting chemotherapy The safety of this treatment will be evaluated and researchers want to learn if NK cells will help in treating acute myeloid leukemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None